Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs ODM 104 (Primary) ; Carbidopa; Levodopa; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Acronyms NOCOF
- Sponsors Orion
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Dec 2014 New trial record